Ortin Global Ltd (IN:ORTINGLOBE)
:ORTINGLOBE
Want to see IN:ORTINGLOBE full AI Analyst Report?
Top Page
Ortin Global Ltd
(ORTINGLOBE)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹17.50
▲(51.52% Upside)
Action:Reiterated
Date:06/10/26
The score is weighed down primarily by severe financial weakness (negative gross profit, very large losses, negative operating cash flow, and higher leverage). Technicals are supportive with price strength and positive MACD, but overbought signals temper the outlook. Valuation remains constrained by loss-making results and no indicated dividend yield.
Positive Factors
Revenue Growth
A 69.5% revenue increase in FY2026 indicates meaningful demand traction and top-line momentum. Sustained revenue growth provides a platform to leverage fixed costs, negotiate better supplier terms, and invest in commercialization, supporting recovery if margins and operations are tightened.
Negative Factors
Severe Margin Collapse
Extremely negative gross and operating margins show the core business is losing money at an unsustainable rate. Such structural margin deficits indicate product pricing, cost of goods, or operational inefficiencies that must be fixed; failure to do so will continue to destroy value and equity.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A 69.5% revenue increase in FY2026 indicates meaningful demand traction and top-line momentum. Sustained revenue growth provides a platform to leverage fixed costs, negotiate better supplier terms, and invest in commercialization, supporting recovery if margins and operations are tightened.
Read all positive factors
Ortin Global Ltd (ORTINGLOBE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹134.25M
Dividend YieldN/A
Average Volume (3M)4.53K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth-62.82%
EPS Growth12.66%
CountryIN
Employees3
SectorServices
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.82
Shares Outstanding8,131,392
10 Day Avg. Volume4,815
30 Day Avg. Volume4,526
Financial Highlights & Ratios
PEG Ratio1.24
Price to Book (P/B)9.31
Price to Sales (P/S)114.55
P/FCF Ratio-20.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ortin Global Ltd Business Overview & Revenue Model
Company Description
Ortin Global Ltd., established in 1986 and headquartered in Hyderabad, India, is an Indian enterprise specializing in the manufacturing and trading of pharmaceuticals, drugs, and their intermediates. The company, formerly known as Ortin Laboratori...
How the Company Makes Money
null...
Ortin Global Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 593.00K | 1.00M | 3.42M |
| Gross Profit | 502.00K | -1.52M | 1.28M |
| EBITDA | -6.61M | -7.21M | -8.23M |
| Net Income | -6.67M | -7.40M | -8.46M |
Balance Sheet | |||
| Total Assets | 38.26M | 46.47M | 37.81M |
| Cash, Cash Equivalents and Short-Term Investments | 3.18M | 6.06M | 3.74M |
| Total Debt | 9.30M | 10.05M | 2.50M |
| Total Liabilities | 25.26M | 34.10M | 18.03M |
| Stockholders Equity | 13.00M | 12.37M | 19.77M |
Cash Flow | |||
| Free Cash Flow | -9.15M | -5.60M | -4.14M |
| Operating Cash Flow | -9.12M | -5.62M | -4.10M |
| Investing Cash Flow | 374.00K | 390.00K | -36.00K |
| Financing Cash Flow | 8.26M | 7.55M | 3.28M |
Ortin Global Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹1.16B | 9.10 | ― | ― | 2.66% | -1.90% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
51 Neutral | ₹576.91M | 20.74 | ― | ― | -14.99% | 399.30% | |
49 Neutral | ₹134.25M | -21.37 | ― | ― | -62.82% | 12.66% | |
49 Neutral | ₹378.26M | -1.15 | ― | ― | -82.35% | -130.97% | |
43 Neutral | ₹477.22M | -1.07 | ― | ― | -26.89% | -760.69% | |
39 Underperform | ₹491.68M | -1.42 | ― | ― | -35.33% | -65.64% |
* Services Sector Average
IN:ORTINGLOBE
Ortin Global Ltd
16.21
4.21
35.08%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
35.53
-10.99
-23.62%
IN:LASA
Lasa Supergenerics Ltd.
7.30
-2.13
-22.59%
IN:MANGALAM
Mangalam Drugs & Organics Ltd.
29.94
-49.74
-62.42%
IN:PAR
Par Drugs and Chemicals Limited
94.67
-1.30
-1.35%
IN:VIVIMEDLAB
Vivimed Labs Limited
5.99
1.09
22.24%
Ortin Global Ltd Corporate Events
Ortin Global Says It Does Not Qualify as SEBI-Defined Large Corporate for FY 2026–27
May 6, 2026
Ortin Global Ltd has notified the stock exchanges that it does not qualify as a “Large Corporate” under the Securities and Exchange Board of India’s October 2023 framework, which applies to listed entities meeting specified thres...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.